Nonsteroidal Anti-inflammatory Drugs and the Risk of Parkinson Disease
The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Nonsteroidal anti-inflammatory drugs (NSAIDs) reduce dopaminergic neuron degeneration in animal models of Parkinson disease (PD). However, no epidemiological data have been available on NSAID use and the risk of PD. OBJECTIVE: To investigate prospectively whether the use of nonaspirin NSAIDs or aspirin is associated with decreased PD risk. DESIGN, SETTINGS, AND PARTICIPANTS: Prospective cohorts of 44 057 men and 98 845 women free of PD, stroke, or cancer (Health Professionals Follow-up Study, 1986-2000, and Nurses' Health Study, 1980-1998). Main Outcome Measure Newly diagnosed PD. RESULTS: We documented 415 incident PD cases (236 men and 179 women). Participants who reported regular use of nonaspirin NSAIDs at the beginning of the study had a lower risk of PD than nonregular users during the follow-up; the pooled multivariate relative risk was 0.55 (95% confidence interval, 0.32-0.96, P =.04). Compared with nonusers, a nonsignificantly lower risk of PD was also observed among men and women who took 2 or more tablets of aspirin per day (relative risk, 0.56; 95% confidence interval, 0.26-1.21). CONCLUSION: These findings are consistent with the hypothesis that use of NSAIDs may delay or prevent the onset of PD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
McGeer, P. L., Itagaki, S., Boyes, B. E., & McGeer, E. G. (1988) · Neurology · doi:10.1212/wnl.38.8.1285 · Cited by 2,990
Rimm, E. B., Giovannucci, E. L., Stampfer, M. J., Colditz, G. A., Litin, L. B., & Willett, W. C. (1992) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a116211 · Cited by 2,104
Self-citationLang, A. E., & Lozano, A. M. (1998) · New England Journal of Medicine · doi:10.1056/nejm199810083391506 · Cited by 1,994
MCGEER, P., & MCGEER, E. (1995) · Brain Research Reviews · doi:10.1016/0165-0173(95)00011-9 · Cited by 1,287 · cited 1×
“Moreover, our results are also consistent with the previous epidemiological support of a protective effect of NSAIDs on the risk of Alzheimer disease,(8,9) for which similar biological hypotheses have been proposed.(6,7) A protective role of NSAIDs in the central nervous system seems therefore likely and should be add…”
Nonsteroidal Antiinflammatory Drugs and the Risk of Alzheimer's Disease
in 't Veld, B. A., Ruitenberg, A., Hofman, A., Launer, L. J., van Duijn, C. M., Stijnen, T., Breteler, M. M. B., & Stricker, B. H. C. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010178 · Cited by 1,196
Risk of Alzheimer's disease and duration of NSAID use
Stewart, W. F., Kawas, C., Corrada, M., & Metter, E. J. (1997) · Neurology · doi:10.1212/wnl.48.3.626 · Cited by 1,132
Aspirin and the Risk of Colorectal Cancer in Women
Giovannucci, E., Egan, K. M., Hunter, D. J., Stampfer, M. J., Colditz, G. A., Willett, W. C., & Speizer, F. E. (1995) · New England Journal of Medicine · doi:10.1056/nejm199509073331001 · Cited by 1,090
Self-citationMogi, M., Harada, M., Kondo, T., Riederer, P., Inagaki, H., Minami, M., & Nagatsu, T. (1994) · Neuroscience Letters · doi:10.1016/0304-3940(94)90508-8 · Cited by 855
Improved accuracy of clinical diagnosis of Lewy body Parkinson’s disease
Hughes, A. J., Daniel, S. E., & Lees, A. J. (2001) · Neurology · doi:10.1212/wnl.57.8.1497 · Cited by 807
Anti-inflammatory drugs and their mechanism of action
Vane, J. R., & Botting, R. M. (1998) · Inflammation Research · doi:10.1007/s000110050284 · Cited by 798
Aspirin Use and the Risk for Colorectal Cancer and Adenoma in Male Health Professionals
Giovannucci, E., Rimm, E. B., Stampfer, M. J., Colditz, G. A., Ascherio, A., & Willett, W. C. (1994) · Annals of Internal Medicine · doi:10.7326/0003-4819-121-4-199408150-00001 · Cited by 785
Self-citationAssociation of coffee and caffeine intake with the risk of Parkinson disease
Ross, G. W. (2000) · JAMA · doi:10.1001/jama.283.20.2674 · Cited by 778
Neuroprotection by Aspirin and Sodium Salicylate Through Blockade of NF-κB Activation
Grilli, M., Pizzi, M., Memo, M., & Spano, P. (1996) · Science · doi:10.1126/science.274.5291.1383 · Cited by 750
The Nurses' Health Study: 20-Year Contribution to the Understanding of Health Among Women
COLDITZ, G. A., MANSON, J. E., & HANKINSON, S. E. (1997) · Journal of Women's Health · doi:10.1089/jwh.1997.6.49 · Cited by 743
Self-citationHunot, S., Brugg, B., Ricard, D., Michel, P. P., Muriel, M.-P., Ruberg, M., Faucheux, B. A., Agid, Y., & Hirsch, E. C. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.14.7531 · Cited by 678
Prospective Study of Caffeine Consumption and Risk of Parkinson’s Disease in Men and Women
Ascherio, A., Zhang, S. M., Hernán, M. A., Kawachi, I., Colditz, G. A., Speizer, F. E., & Willett, W. C. (2001) · Annals of Neurology · doi:10.1002/ana.1052 · Cited by 677 · cited 2×
“Furthermore, our results on NSAIDs were similar in men and women, whereas caffeine was inversely associated with PD risk only among men.(12) The environmental factors that have been found to be strongly related to PD risk in our cohorts and others include smoking(19,20) (inverse association) and caffeine intake(12,21)…”
Self-citationCicchetti, F., Brownell, A. L., Williams, K., Chen, Y. I., Livni, E., & Isacson, O. (2002) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2002.01938.x · Cited by 406
Kurkowska-Jastrzębska, I., Wrońska, A., Kohutnicka, M., Członkowski, A., & Członkowska, A. (1999) · Experimental Neurology · doi:10.1006/exnr.1998.6993 · Cited by 379
Glial cells and inflammation in parkinson's disease: A role in neurodegeneration?
Hirsch, E. C., Hunot, S., Damier, P., & Faucheux, B. (1998) · Annals of Neurology · doi:10.1002/ana.410440717 · Cited by 334
Teismann, P., & Ferger, B. (2001) · Synapse · doi:10.1002/1098-2396(200102)39:2<167::aid-syn8>3.0.co;2-u · Cited by 306
A Prospective Study of Aspirin Use and Primary Prevention of Cardiovascular Disease in Women
Manson, J. E. (1991) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1991.03470040085027 · Cited by 272
Prospective Study of Cigarette Smoking and the Risk of Developing Idiopathic Parkinson's Disease
Grandinetti, A., Morens, D. M., Reed, D., & MacEachern, D. (1994) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a116960 · Cited by 220
Aspirin and Salicylate Protect Against MPTP‐Induced Dopamine Depletion in Mice
Aubin, N., Curet, O., Deffois, A., & Carter, C. (1998) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1998.71041635.x · Cited by 214
Cigarette smoking and the incidence of Parkinson's disease in two prospective studies
Hernán, M. A., Zhang, S. M., Rueda‐DeCastro, A. M., Colditz, G. A., Speizer, F. E., & Ascherio, A. (2001) · Annals of Neurology · doi:10.1002/ana.10028 · Cited by 191
Self-citationAsanuma, M., Nishibayashi‐Asanuma, S., Miyazaki, I., Kohno, M., & Ogawa, N. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00205.x · Cited by 188
Caffeinated clues and the promise of adenosine A2Aantagonists in PD
Schwarzschild, M. A., Chen, J.-F., & Ascherio, A. (2002) · Neurology · doi:10.1212/wnl.58.8.1154 · Cited by 161
Self-citationIbuprofen protects dopaminergic neurons against glutamate toxicity in vitro
Casper, D., Yaparpalvi, U., Rempel, N., & Werner, P. (2000) · Neuroscience Letters · doi:10.1016/s0304-3940(00)01294-5 · Cited by 153
Mohanakumar, K. P., Muralikrishnan, D., & Thomas, B. (2000) · Brain Research · doi:10.1016/s0006-8993(00)02189-2 · Cited by 122
McGeer, P. L. (2000) · Drugs & Aging · doi:10.2165/00002512-200017010-00001 · Cited by 118
Ferger, B., Teismann, P., Earl, C. D., Kuschinsky, K., & Oertel, W. H. (1999) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s002109900079 · Cited by 71
Hydroxyl Radical Scavenging Activity of Nonsteroidal Anti-Inflammatory Drugs
Kataoka, M., Tonooka, K., Ando, T., Imai, K., & Aimoto, T. (1997) · Free Radical Research · doi:10.3109/10715769709065781 · Cited by 61
Langston, J. W., Forno, L. S., Tetrud, J., Reeves, A. G., Kaplan, J. A., & Karluk, D. (1999) · Annals of Neurology · doi:10.1002/1531-8249(199910)46:4 · Cited by 1
Cited by
Epidemiology of Parkinson's disease
de Lau, L. M., & Breteler, M. M. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70471-9 · Cited by 4,110
Neuroinflammation in Parkinson’s disease: A target for neuroprotection?
Hirsch, E. C., & Hunot, S. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70062-6 · Cited by 1,984
The epidemiology of Parkinson's disease: risk factors and prevention
Ascherio, A., & Schwarzschild, M. A. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)30230-7 · Cited by 1,825
Self-citationInflammation and immune dysfunction in Parkinson disease
Tansey, M. G., Wallings, R. L., Houser, M. C., Herrick, M. K., Keating, C. E., & Joers, V. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-022-00684-6 · Cited by 1,382
Epidemiology and etiology of Parkinson's disease: a review of the evidence
Wirdefeldt, K., Adami, H.-O., Cole, P., Trichopoulos, D., & Mandel, J. (2011) · European Journal of Epidemiology · doi:10.1007/s10654-011-9581-6 · Cited by 1,199
Metadata
- Authors
- Chen, H., Zhang, S. M., Hernán, M. A., Schwarzschild, M. A., Willett, W. C., Colditz, G. A., Speizer, F. E., & Ascherio, A.
- Venue
- Archives of Neurology
- Publisher
- American Medical Association (AMA)
- Published
- 2003-08-01
- Volume
- 60
- Issue
- 8
- Pages
- 1059
- ISSN
- 0003-9942 (ISSN-L)
- OpenAlex
- W2100042702
- Cited by
- 634
- References
- 33
- FWCI
- 18.85
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.